SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-22-000083
Filing Date
2022-11-02
Accepted
2022-11-02 16:22:10
Documents
62
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20220930.htm   iXBRL 10-Q 1659982
2 EX-31.1 allo-20220930xex311.htm EX-31.1 9890
3 EX-31.2 allo-20220930xex312.htm EX-31.2 9860
4 EX-32.1 allo-20220930xex321.htm EX-32.1 7124
  Complete submission text file 0001737287-22-000083.txt   6805977

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20220930.xsd EX-101.SCH 46058
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20220930_cal.xml EX-101.CAL 50480
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20220930_def.xml EX-101.DEF 237766
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20220930_lab.xml EX-101.LAB 596572
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20220930_pre.xml EX-101.PRE 366916
56 EXTRACTED XBRL INSTANCE DOCUMENT allo-20220930_htm.xml XML 1068344
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 221354447
SIC: 2836 Biological Products, (No Diagnostic Substances)